Drug intelligence / Profile preview

ANR 82

Development stage: Preclinical
Modality: Small Molecules

Overview

ANR 82 is an 8-bromo-9-ethyladenine derivative, classified as a small molecule. It functions as an antagonist of the adenosine A2A receptor. Preclinical studies have demonstrated its ability to reverse haloperidol-induced catalepsy in rat models of Parkinson's disease, suggesting a potential therapeutic role for ameliorating motor deficits associated with the condition.

Other names: 8-bromo-9-ethyladenine

Targets

ADORA2A (Adenosine A₂A Receptor)

Beyond the preview

Go deeper on ANR 82.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANR 82.

Explore the full profile